FHIR R4 Current Build
This page is part of FHIR R4 - the current version v4.0.0 - in it's permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions .

4.3.14.349 4.3.14.361 Code System http://terminology.hl7.org/CodeSystem/research-study-phase

Biomedical Research and Regulation Work Group   Maturity Level : 1 Draft Use Context : Any

This is a code system defined by the FHIR project.

Summary

Defining URL: http://terminology.hl7.org/CodeSystem/research-study-phase
Version: 4.0.0 4.1.0
Name: ResearchStudyPhase
Title: ResearchStudyPhase
Definition:

Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.

Committee: Biomedical Research and Regulation Work Group
OID: 2.16.840.1.113883.4.642.1.1247 (for OID based terminology systems)
Source Resource XML / JSON

This Code system is used in the following value sets:

  • ValueSet: ResearchStudyPhase (Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.)
  • ValueSet: ResearchStudyPhase (Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.)

Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.

This code system http://terminology.hl7.org/CodeSystem/research-study-phase defines the following codes:
Code Display Definition
n-a N/A Trials without phases (for example, studies of devices or behavioral interventions).
early-phase-1 Early Phase 1 Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
phase-1 Phase 1 Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
phase-1-phase-2 Phase 1/Phase 2 Trials that are a combination of phases 1 and 2.
phase-2 Phase 2 Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
phase-2-phase-3 Phase 2/Phase 3 Trials that are a combination of phases 2 and 3.
phase-3 Phase 3 Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
phase-4 Phase 4 Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

 

See the full registry of code systems defined as part of FHIR.


Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. See Code System for further information.
Source The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance). If the code is in italics, this indicates that the code is not selectable ('Abstract')
Display The display (used in the display element of a Coding ). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code